专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1992013890A1 NEMATODE VACCINE 审中-公开
公开(公告)号：WO1992013890A1
公开(公告)日：1992-08-20
申请号：PCT/AU1992000041
申请日：1992-02-06
申请人： BIOTECH AUSTRALIA PTY LIMITED , COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ... , SHARP, Phillip, John , WAGLAND, Barry, Maxwell
发明人： BIOTECH AUSTRALIA PTY LIMITED , COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ...
IPC分类号： C07K15/08
CPC分类号： C07K16/18 , A61K39/00 , C07K14/4354 , C12N2799/026
摘要： A substantially purified antigen derived from a first parasitic nematode species which, when administered to a host animal, is capable of protecting the host animal from infestation by a second parasitic nematode species, wherein the first and second parasitic nematode species may be the same or different, and the antigen has an apparent molecular weight of 40 kD as determined by SDS-PAGE under reducing conditions.
摘要翻译：一种基本上纯化的抗原，其来源于第一寄生线虫物种，其在施用于宿主动物时能够通过第二寄生线虫种保护宿主动物免于侵染，其中第一和第二寄生线虫物种可以相同或不同，并且抗原在还原条件下通过SDS-PAGE测定具有40kD的表观分子量。

2. 发明申请

WO1991019003A1 DETECTION PROCESS 审中-公开
标题翻译：检测过程
公开(公告)号：WO1991019003A1
公开(公告)日：1991-12-12
申请号：PCT/AU1991000247
申请日：1991-06-07
申请人： BIOTECH AUSTRALIA PTY LIMITED , FARR, Lester, John , ATRACHE, Vincent, Habib , BRAID, Geoffrey, Harold , HARRISON, David, Ernest, Forester
发明人： BIOTECH AUSTRALIA PTY LIMITED
IPC分类号： C12Q01/04
CPC分类号： G01N33/569 , C12Q1/04
摘要： This invention relates to processes for the detection and/or enumeration of contaminants in samples such as pharmaceutical samples, food, beverage and water samples. The processes combine the specificity of immunodetection with the speed of automated systems to provide rapid methods for the detection of specific contaminants in samples.
摘要翻译：本发明涉及用于检测和/或计数样品中的污染物的方法，例如药物样品，食品，饮料和水样品。该过程将免疫检测的特异性与自动化系统的速度相结合，为检测样品中的特定污染物提供快速方法。

3. 发明申请

US20070172461A1 Polyepitope vaccines 审中-公开
标题翻译：多表面疫苗
公开(公告)号：US20070172461A1
公开(公告)日：2007-07-26
申请号：US10884183
申请日：2004-07-02
申请人： Andreas Suhrbier , Scott Thomson , Rajiv Khanna , Scott Burrows , Barbara Elizabeth Coupar , Denis Moss
发明人： Andreas Suhrbier , Scott Thomson , Rajiv Khanna , Scott Burrows , Barbara Elizabeth Coupar , Denis Moss
IPC分类号： A61K48/00 , A61K39/275 , A61K39/285 , A61K39/02
CPC分类号： A61K39/00 , C12N15/86 , C12N2760/16122
摘要： The present invention relates to a recombinant polyepitope cytotoxic T lymphocyte vaccine. The vaccine comprises at least one recombinant protein including a plurality of cytotoxic T lymphocyte epitopes from one or more pathogens, wherein the at least one recombinant protein is substantially free of sequences naturally found to flank the cytotoxic T lymphocyte epitopes. In addition the present invention also provides a polynucleotide including at least one sequence encoding a plurality of cytotoxic T lymphocyte epitopes from one or more pathogens.
摘要翻译：本发明涉及重组多表位细胞毒性T淋巴细胞疫苗。所述疫苗包含至少一种重组蛋白，其包含来自一种或多种病原体的多种细胞毒性T淋巴细胞表位，其中所述至少一种重组蛋白基本上不含天然存在于所述细胞毒性T淋巴细胞表位侧翼的序列。此外，本发明还提供了包含至少一种编码来自一种或多种病原体的多种细胞毒性T淋巴细胞表位的序列的多核苷酸。

4. 发明授权

US5869466A Vitamin B.sub.12 mediated oral delivery systems for GCSF 失效
标题翻译：维生素B12介导的GCSF口服递送系统
公开(公告)号：US5869466A
公开(公告)日：1999-02-09
申请号：US651541
申请日：1996-05-22
申请人： Gregory John Russell-Jones , Steven William Westwood
发明人： Gregory John Russell-Jones , Steven William Westwood
IPC分类号： A61K31/714 , A61K38/00 , A61K47/48 , C07K1/113 , C07K14/505 , C07K14/535 , C07K17/02 , C07K17/08 , C07K17/10 , A61K31/70 , C07H23/00 , C07K1/00
CPC分类号： A61K47/48169 , A61K47/48023 , A61K47/48176 , C07K14/505 , C07K14/535 , C07K17/02 , A61K38/00
摘要： The invention describes complexes between VB.sub.12 analogues and either GCSF or EPO that retain both significant affinity for intrinsic factor (IF) in the VB.sub.12 portion of the complex and significant bioactivity of the GCSF or EPO portion of the complex. The invention also concerns a process for the synthesis of these complexes. This is achieved at least in part, by using a spacer compound, which is linked covalantly between the VB.sub.12 portion and the GCSF or EPO. The complexes preferably have the formulaV--X--A--Y--ZwhereinV is vitamin B.sub.12 or a vitamin B.sub.12 analogue, or derivative, bonded to X either through a carboxylate group pendant to the corrin nucleus of VB.sub.12 or through the central cobalt atom or to a functional group introduced onto the VB.sub.12 molecule, X is selected from: --NHNH--, --NH--, --O--, --S--, --SS--or --CH.sub.2 --, and A is an optionally substituted, saturated or unsaturated, branched or linear, C.sub.1-50 alkylene, cycloalkylene or aromatic group, optionally with one or more carbons within the linear chain being replaced with N, O or S, and wherein the optional substituents are selected from carbonyl, carboxy, hydroxy, amino and other groups, and Y is the covalent linkage between A and Z where Y is selected from --NHCO--, --CONH--, --CONHNHCO--, --N.dbd.N--, --N.dbd.CH--,--NHCH--, --NHN.dbd.CH--, --NHNHCH.sub.2 --, --SS--, --SCH.sub.2 --, --CH.sub.2 S--, --NHCRNH--, --COO--, --OCO--, and R is O, S or NH.sub.2, and Z is GCSF or EPO. The invention also describes reagents that can be used as probes for the detection of buried thiol groups of a protein or peptide, said reagent comprising a complex of either vitamin B.sub.12 (or an analogue thereof) or more generally of any instrumentally or visually detectable label, covalently linked to a diradical spacer, said spacer having a terminal reactive group capable of forming a disulphide bond with a free thiol in said protein or peptides.
摘要翻译：本发明描述了VB12类似物和GCSF或EPO之间的复合物，其在复合物的VB12部分中保留对内在因子（IF）的显着亲和力，并且复合物的GCSF或EPO部分具有显着的生物活性。本发明还涉及合成这些络合物的方法。这通过使用在VB12部分和GCSF或EPO之间共价连接的间隔体化合物至少部分地实现。络合物优选具有式VXAYZ，其中V是维生素B12或维生素B12类似物或衍生物，其通过悬浮于VB12的corrin核的羧酸酯基团或通过中心钴原子或导入到 VB12分子，X选自：-NHN - ， - NH - ， - O - ， - S - ， - S - 或-CH 2 - ，A是任选取代的，饱和或不饱和的，支链或直链的C1-50 任选与线性链中的一个或多个碳原子的亚烷基，亚环烷基或芳族基团被N，O或S取代，其中任选的取代基选自羰基，羧基，羟基，氨基和其它基团，Y是共价键其中Y选自-NHCO - ， - CONH - ， - CONHNHCO - ， - N = N - ， - N = CH - ， - NHCH - ， - NHN = CH - ， - NHNHCH2-，-SS - ， - CH 2 - ， - CH 2 S - ， - NHCRN - ， - COO - ， - OCO-，R是O，S或NH 2，Z是GCSF或EPO。本发明还描述了可用作检测蛋白质或肽的掩埋硫醇基团的探针的试剂，所述试剂包含维生素B12（或其类似物）或更通常的任何仪器上或视觉上可检测的标记物的复合物，共价连接到双基间隔物上，所述间隔物具有能与所述蛋白质或肽中的游离硫醇形成二硫键的末端反应基团。

5. 发明授权

US5807832A Oral delivery of biologically active substances bound to vitamin B.sub.12 失效
公开(公告)号：US5807832A
公开(公告)日：1998-09-15
申请号：US483811
申请日：1995-06-07
申请人： Gregory John Russell-Jones , Peter Howe , Henry James de Aizpurua , Geoffery Lewis Burge
发明人： Gregory John Russell-Jones , Peter Howe , Henry James de Aizpurua , Geoffery Lewis Burge
IPC分类号： A61K47/48 , A61K31/68 , A61K38/09 , A61K38/41 , A61K39/00
CPC分类号： A61K47/48023
摘要： Complex of a drug, hormone, bio-active peptide, or immunogen with the carrier molecule vitamin B12 and a method for delivering the complex to the intestine of a host vertebrate in order to deliver the complex to the circulation of the host and thereby elicit a pharmacological response to the drug, hormone, bio-active molecule or to elicit a systemic immune response to the immunogen. The invention also provides a method for the production of the complex. Further, the invention provides medicaments containing the complex.

6. 发明授权

US5525508A Haemonchus contortus vaccine 失效
标题翻译：血矛线虫疫苗
公开(公告)号：US5525508A
公开(公告)日：1996-06-11
申请号：US930686
申请日：1992-10-06
申请人： Phillip J. Sharp , Barry M. Wagland , Gary S. Cobon
发明人： Phillip J. Sharp , Barry M. Wagland , Gary S. Cobon
IPC分类号： A61K39/00 , A61K38/00 , A61K39/395 , A61P33/10 , C07K1/22 , C07K14/00 , C07K14/435 , C07K16/00 , C12N15/09 , C12N15/12 , C12P21/02 , A61K39/002 , C07K14/44 , C12N15/30
CPC分类号： C07K14/4354 , A61K38/00 , Y10S530/822
摘要： A substantially purified antigen derived from a first species of parasitic nematodes, which antigen is capable of providing protection to a host from parasitism by a second nematode species, which may be the same as or different from the first nematode species, following vaccination of the host with the antigen, characterized in that the antigen is proteinaceous, has a pI between 3.8 and 4.4, can be bound by lentil lectin and Helix promatia lectin and has a molecular weight of approximately 45 kD as determined by SDS-PAGE.
摘要翻译： PCT No.PCT / AU92 / 00040 Sec。 371日期：1992年10月6日 102（e）日期1992年10月6日PCT提交1992年2月5日PCT公布。公开号WO92 / 13889 日期：1992年8月20日。来自第一种寄生线虫的基本上纯化的抗原，其抗原能够通过第二线虫种类向寄主提供保护，其可以与第一线虫相同或不同其特征在于抗原是蛋白质的，具有3.8至4.4之间的pI，可以被扁豆凝集素和螺旋状突变型凝集素结合，并具有由SDS测定的约45kD的分子量 -页。

7. 发明授权

US5548064A Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions 失效
标题翻译：维生素B12与EPO的缀合物，其类似物和药物组合物
公开(公告)号：US5548064A
公开(公告)日：1996-08-20
申请号：US64873
申请日：1993-05-24
申请人： Gregory J. Russell-Jones , Steven W. Westwood
发明人： Gregory J. Russell-Jones , Steven W. Westwood
IPC分类号： A61K31/714 , A61K38/00 , A61K47/48 , C07K1/113 , C07K14/505 , C07K14/535 , C07K17/02 , C07K17/08 , C07K17/10 , C07H23/00 , C07K2/00
CPC分类号： A61K47/48169 , A61K47/48023 , A61K47/48176 , C07K14/505 , C07K14/535 , C07K17/02 , A61K38/00
摘要： The invention describes complexes between VB.sub.12 analogues and either GCSF or EPO that retain both significant affinity for intrinsic factor (IF) in the VB.sub.12 portion of the complex and significant bioactivity of the GCSF or EPO portion of the complex. The invention also concerns a process for the synthesis of these complexes. This is achieved at least in part, by using a spacer compound, which is linked covalantly between the VB.sub.12 portion and the GCSF or EPO. The complexes preferably have the formulaV--X--A--Y--ZwhereinV is vitamin B.sub.12 or a vitamin B.sub.12 analogue, or derivative, bonded to X either through a carboxylate group pendant to the corrin nucleus of VB.sub.12 or through the central cobalt atom or to a functional group introduced onto the VB.sub.12 molecule, X is selected from: --NHNH--, --NH--, --O--, --S--, --SS--or --CH.sub.2 --, and A is an optionally substituted, saturated or unsaturated, branched or linear, C.sub.1-50 alkylene, cycloalkylene or aromatic group, optionally with one or more carbons within the linear chain being replaced with N, O or S, and wherein the optional substituents are selected from carbonyl, carboxy, hydroxy, amino and other groups, and Y is the covalent linkage between A and Z where Y is selected from --NHCO--, --CONH--, --CONHNHCO--, --N.dbd.N--, --N.dbd.CH--, --NHCH.sub.2 --, --NHN.dbd.CH--, --NHNHCH.sub.2 --, --SS--, --SCH.sub.2 --, --CH.sub.2 S--, --NHCRNH--, --COO--, --OCO--, and R is O, S or NH.sub.2, and Z is GCSF or EPO. The invention also describes reagents that can be used as probes for the detection of buried thiol groups of a protein or peptide, said reagent comprising a complex of either vitamin B.sub.12 (or an analogue thereof) or more generally of any instrumentally or visually detectable label, covalently linked to a diradical spacer, said spacer having a terminal reactive group capable of forming a disulphide bond with a free thiol in said protein or peptides.
摘要翻译：本发明描述了VB12类似物和GCSF或EPO之间的复合物，其在复合物的VB12部分中保留对内在因子（IF）的显着亲和力，并且复合物的GCSF或EPO部分具有显着的生物活性。本发明还涉及合成这些络合物的方法。这通过使用在VB12部分和GCSF或EPO之间共价连接的间隔化合物至少部分地实现。络合物优选具有式V-XAY-Z，其中V是维生素B12或维生素B12类似物或衍生物，其通过悬浮于VB12的corrin核的羧酸酯基团或通过中心钴原子或引入的官能团在VB12分子上，X选自：-NHN - ， - NH - ， - O - ， - S - ， - S - 或-CH 2 - ，A是任选取代的饱和或不饱和的支链或直链C1 -50个亚烷基，亚环烷基或芳基，任选与一个或多个直链内的碳被N，O或S取代，其中任选的取代基选自羰基，羧基，羟基，氨基和其它基团，Y是其中Y选自-NHCO - ， - CONH - ， - CONHNHCO - ， - N = N - ， - N = CH - ， - NHCH 2 - ， - NHN = CH - ， - NHNHCH 2 - ， - -SS - ， - CH 2 - ， - CH 2 S - ， - NHCRNH-，-COO-，-OCO-，R是O，S或NH 2，Z是GCSF或EPO。本发明还描述了可用作检测蛋白质或肽的掩埋硫醇基团的探针的试剂，所述试剂包含维生素B12（或其类似物）或更通常的任何仪器上或视觉上可检测的标记物的复合物，共价连接到双基间隔物上，所述间隔物具有能与所述蛋白质或肽中的游离硫醇形成二硫键的末端反应基团。

8. 发明授权

US5444153A Variants of PAI-2 失效
标题翻译： PAI-2的变体
公开(公告)号：US5444153A
公开(公告)日：1995-08-22
申请号：US768286
申请日：1991-10-11
申请人： Neil H. Goss , Michael A. Richardson
发明人： Neil H. Goss , Michael A. Richardson
IPC分类号： G01N33/53 , A61K38/55 , A61K39/395 , A61K49/00 , A61K51/00 , A61P7/04 , A61P29/00 , A61P35/00 , C07K14/00 , C07K14/81 , C07K16/00 , C07K19/00 , C12N1/21 , C12N5/10 , C12N9/99 , C12N15/09 , C12N15/15 , C12P21/02 , C12P21/08 , C12R1/19 , G01N33/577 , C12Q1/00
CPC分类号： C07K14/8132
摘要： Variants of the plasminogen activator inhibitor PAI-2 in which the 66-98 amino acid residue region has been altered to eliminate at least one protease sensitive site are provided. The variants of the invention maintain the biological activity of PAI-2 and amino acids up to 65 and from 99 of PAI-2 in frame. The PAI-2 variants of the invention in labelled form, as well as DNA molecules encoding the variants of the invention, transformed host cells expressing the variants of the invention compositions and diagnostic kits comprising the variants of the invention, antibodies against the variants of the invention and processes for the production of the variants, DNA molecules, transformed hosts, compositions and antibodies of the invention are also described.
摘要翻译： PCT No.PCT / AU90 / 00603 Sec。 371日期1991年10月11日 102（e）日期1991年10月11日PCT 1990年12月20日PCT PCT。出版物WO91 / 09124 日期：1991年6月27日。提供其中66-98个氨基酸残基区被改变以消除至少一个蛋白酶敏感位点的纤溶酶原激活物抑制剂PAI-2的变体。本发明的变体在框架中保持PAI-2和PAI-2的最高65和99的氨基酸的生物活性。标记形式的本发明的PAI-2变体以及编码本发明变体的DNA分子转化表达本发明变体的宿主细胞组合物和包含本发明变体的诊断试剂盒，还描述了用于生产本发明的变体，DNA分子，转化宿主，组合物和抗体的发明和方法。

9. 发明申请

US20050084498A1 EBV CTL epitopes 审中-公开
标题翻译： EBV CTL表位
公开(公告)号：US20050084498A1
公开(公告)日：2005-04-21
申请号：US10752380
申请日：2004-01-06
申请人： Rajiv Khanna , Beverley Kerr , Ihor Misko , Denis Moss , Scott Burrows
发明人： Rajiv Khanna , Beverley Kerr , Ihor Misko , Denis Moss , Scott Burrows
IPC分类号： A61K39/00 , C07K14/05 , A61K39/12 , C07K7/08 , C07K14/005
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/51 , C12N2710/16222 , Y02A50/466
摘要： The present invention provides cytotoxic Epstein-Barr virus T-cell epitopes. These epitopes are QVKWRMTTL, VFSDGRVAC, VPAPAGPIV, TYSAGIVQI, LLDFVRFMGV, QNGALAINTF, VSSDGRVAC, VSSEGRVAC, VSSDGRVPC, VSSDGLVAC, VSSDGQVAC, VSSDGRVVC, VPAPPVGPIV, VEITPYEPTG, VEITPYEPTW, VELTPYKPTW, RRIYDLIKL, RKIYDLIEL and PYLFWLAGI. The present invention further provides vaccines including one or more of these epitopes, optionally with additional epitopes.
摘要翻译：本发明提供细胞毒性的爱泼斯坦 - 巴尔病毒T细胞表位。这些表位是QVKWRMTTL，VFSDGRVAC，VPAPAGPIV，TYSAGIVQI，LLDFVRFMGV，QNGALAINTF，VSSDGRVAC，VSSEGRVAC，VSSDGRVPC，VSSDGLVAC，VSSDGQVAC，VSSDGRVVC，VPAPPVGPIV，VEITPYEPTG，VEITPYEPTW，VELTPYKPTW，RRIYDLIKL，RKIYDLIEL和PYLFWLAGI。本发明进一步提供包含一种或多种这些表位的疫苗，任选具有另外的表位。

10. 发明授权

US5942413A Nematode vaccine 失效
标题翻译：线虫疫苗
公开(公告)号：US5942413A
公开(公告)日：1999-08-24
申请号：US460998
申请日：1995-06-05
申请人： Phillip John Sharp , Barry Maxwell Wagland , Gary Stewart Cobon
发明人： Phillip John Sharp , Barry Maxwell Wagland , Gary Stewart Cobon
IPC分类号： A61K39/00 , A61K38/00 , A61K39/395 , A61P33/10 , C07K1/22 , C07K14/00 , C07K14/435 , C07K16/00 , C12N15/09 , C12N15/12 , C12P21/02 , C12N15/11 , A61K39/002 , C12N15/30
CPC分类号： C07K14/4354 , A61K38/00 , Y10S530/822
摘要： Disclosed is a substantially purified antigen derived from a first species of parasitic nematodes, which antigen is capable of providing protection to a host from parasitism infestation by a second nematode species, which may be the same as or different from the first nematode species, following vaccination of the host with the antigen, characterized in that the antigen is proteinaceous, has a pI between 3.8 and 4.4, can be bound by lentil lectin and Helix promatia and has a molecular weight of approximately 45 kD as determined by SDS-PAGE.
摘要翻译：公开了源自第一种寄生线虫的基本上纯化的抗原，该抗原能够在接种后能够向宿主提供对第一种线虫种类可能相同或不同的第二种线虫的寄生虫侵染的保护的抗原，其特征在于抗原是蛋白质的，具有3.8至4.4之间的pI，可以被扁豆凝集素和螺旋状突起结合，并且通过SDS-PAGE测定具有约45kD的分子量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式